Skip to content
RTBeamTech

Built by physicists.
Driven by patients.

We're a spin-off of LIP and IST, developing the beam-monitoring instruments that make ultra-high-dose-rate radiotherapy, FLASH-RT, safe enough for the clinic.

2026
Founded as LIP/IST spin-off
20+
Years of detector R&D behind the team
<1 µs
Beam response measurement window
3
European and American research partners

Our story

From the lab bench to the treatment room

RTBeamTech began inside the particle-physics labs of LIP and the instrumentation groups at IST, where our founders spent more than a decade designing detectors for high-energy physics experiments at CERN and beyond.

When FLASH radiotherapy started showing the ability to spare healthy tissue at ultra-high dose rates, the medical community ran into a hard limit: existing clinical dosimeters simply could not measure beams that fast. We realised the instruments we'd been building for physics were exactly what oncology needed.

Today we're translating that expertise into certified medical devices — engineered to the precision physics demands and the reliability clinical practice requires.

What we stand for

Principles before products

Every device we ship is judged against four non-negotiables.

⚛︎

Scientific rigour

Every measurement is validated against reference physics standards before it leaves our bench.

Patient safety first

If a measurement isn't reliable, the treatment isn't safe. We design for the worst-case clinical day.

Clinical pragmatism

Built with — not just for — radiotherapy physicists. Our tools fit how a radiotherapy accelerator actually works.

Open collaboration

We publish, partner and contribute. FLASH will only scale if the whole community moves together.

Roadmap

Building the future of FLASH

  1. 2026

    RTBeamTech incorporated

    Founded as a LIP and IST spin-off focused on ultra-fast beam monitoring solutions for FLASH radiotherapy.

  2. 2026

    Prototype validation

    Pilot testing on conventional and dedicated FLASH-RT accelerator platforms with research and clinical partners.

  3. 2027

    Patent and product development

    Advancement of patent protection, product refinement and joint development with industry collaborators.

  4. 2028+

    Clinical translation

    Regulatory strategy, expanded product portfolio and preparation for clinical deployment of FLASH-compatible dosimetry systems.